FDA Approves Genentech ’s Lucentis (ranibizumab) for Myopic Choroidal Neovascularization

South San Francisco, CA -- January 5, 2017 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Lucentis ® (ranibizumab injection) 0.5 mg for the...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news